Keshavarz-Pakseresht Behta, Shandiz Seyed Ataollah Sadat, Baghbani-Arani Fahimeh
Department of Genetics and Biotechnology, School of Biological Science, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran.
Young Researchers and Elite Club, East Tehran Branch, Islamic Azad University, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2017 Winter;10(1):29-33.
The present study investigated the anti-tumor activity of Imatinib mesylate through modulation of gene expression in human hepatocellular carcinoma (HepG2) cell line.
Hepatocellular carcinoma (HCC) is considered to be the third leading cause of cancer related death worldwide. Down regulation of , a metastasis suppressor gene, has been associated with several types of malignant cancer. Recently, effects of Imatinib mesylate, a first member of tyrosine kinases inhibitors, were indicated in research and treatment of different malignant tumors.
Cell viability was quantitated by MTT assay after HepG2 cells exposure to Imatinib mesylate at various concentrations of 0, 1.56, 3.125, 6.25, 12.5, 25,50μM for 24 hours. Also, quantitative real time PCR technique was applied for the detection of gene expression in HepG2 cell line.
There was a dose dependent increase in the cytotoxicity effect of imatinib. The real time PCR results demonstrated that inhibitory effect of Imatinib mesylate on viability via up regulation of gene expression compared to gene (internal control gene) in cancer cells.
According to our findings, imatinib can modulate metastasis by enhancing gene expression in human hepatocellular carcinoma (HepG2) cell line.
本研究通过调节人肝癌（HepG2）细胞系中的基因表达来研究甲磺酸伊马替尼的抗肿瘤活性。
肝细胞癌（HCC）被认为是全球癌症相关死亡的第三大主要原因。一种转移抑制基因的下调与多种恶性肿瘤有关。最近，酪氨酸激酶抑制剂的首个成员甲磺酸伊马替尼的作用在不同恶性肿瘤的研究和治疗中得到了体现。
将HepG2细胞暴露于浓度分别为0、1.56、3.125、6.25、12.5、25、50μM的甲磺酸伊马替尼中24小时后，通过MTT法测定细胞活力。此外，应用定量实时PCR技术检测HepG2细胞系中的基因表达。
伊马替尼的细胞毒性作用呈剂量依赖性增加。实时PCR结果表明，与癌细胞中的基因（内参基因）相比，甲磺酸伊马替尼通过上调基因表达对细胞活力具有抑制作用。
根据我们的研究结果，伊马替尼可通过增强人肝癌（HepG2）细胞系中的基因表达来调节转移。
